Inactive Instrument
Anacor Pharmaceuticals Inc Stock
Stocks
US0324201013
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16-05-26 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
| 16-05-16 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 79 | 2004-01-31 | |
Margaret Madden
PRN | Corporate Officer/Principal | - | 2016-06-23 |
| General Counsel | 77 | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Margaret Madden
BRD | Director/Board Member | - | 2016-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 2016-06-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.80% | -6.98% | -2.73% | +11.12% | 46.38B | |
| +0.17% | -0.74% | +407.28% | +546.58% | 44.51B | |
| -0.86% | -2.60% | +35.51% | +20.35% | 42.3B | |
| -0.14% | -2.98% | -0.04% | +82.21% | 39.91B | |
| 0.00% | -1.72% | +13.42% | +42.33% | 32.79B | |
| -3.44% | -2.43% | - | - | 17.13B | |
| -0.78% | -1.13% | +20.74% | +116.26% | 16.36B | |
| +0.59% | -3.76% | +12.33% | +30.49% | 14.31B | |
| -0.86% | -4.60% | +76.86% | +39.36% | 13.29B | |
| Average | -0.61% | -2.88% | +70.42% | +111.09% | 29.66B | |
| Weighted average by Cap. | -0.32% | -3.04% | +85.97% | +133.03% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
